To Get Help Now
Defective Drug Lawsuits
Click Here
 
Today's Date:

Takeda Announces $2.4 Billion Settlement in Actos Bladder Cancer Cases

In one of the largest product-liability settlements in the pharmaceutical industry, Takeda Pharmaceuticals has agreed to pay $2.4 billion to settle thousands of lawsuits claiming Takeda’s diabetes drug Actos caused bladder cancer.

About 9,000 bladder cancer claims are pending against Takeda, the New York Times reports. Takeda said the settlement would resolve most of the lawsuits involving Actos (pioglitazone). Takeda will take a $2.7 billion charge against earnings to cover the settlement and litigation costs for the remaining cases. More than 3,500 lawsuits brought over Actos have been consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, for pretrial discovery, court dockets indicate. Another 4,500 cases have been filed in state courts in Illinois, West Virginia, California, and Pennsylvania. More Takeda Announces $2.4 Billion Settlement in Actos Bladder Cancer Cases

Diabetes Drug Manufacturer Offers $2.2 Billion to Settle Thousands of Lawsuits

Diabetes Drug Manufacturer Offers $2.2B to Settle

Diabetes Drug Manufacturer Offers $2.2B to Settle


The maker of a top diabetes drug that is linked to cancer and other serious health problems has offered to pay more than $2 billion to lay 8,000 lawsuits to rest.

Takeda Pharmaceutical Co., the maker of the drug Actos, has said it will pay $2.2 billion to settle 8,000 lawsuits filed in federal and state courts on behalf of patients who allege that the company hid cancer risks associated with the diabetes medication, court records show. If the offer is accepted, each plaintiff would receive approximately $275,000. More Diabetes Drug Manufacturer Offers $2.2 Billion to Settle Thousands of Lawsuits

New Deadlines set in Mirena IUD Litigation

New Deadlines set in Mirena IUD Litigation

New Deadlines set in Mirena IUD Litigation


A May 1, 2015 deadline has been set for Bayer Inc. and plaintiffs involved in the Mirena intrauterine device (IUD) litigation to select seven cases to potentially be included in the Second Deposition Pool.

Plaintiffs who wish to have their cases considered for potential inclusion in the Second Deposition Pool must have the Core Criteria in the Plaintiff Fact Sheet completed no later than May 1, 2015, according to a March 17 court order. The Lead Counsel for the Plaintiffs’ Steering Committee (PSC) and Lead Counsel for the Defendants must submit their selections to the court by email by 4:00 p.m. Eastern Standard Time on July 2, 2015. The court order states that these cases should not have unique or idiosyncratic circumstances. Raymond C. Silver, partner at Parker Waichman LLP, has been appointed Co-Lead Counsel in the litigation. More New Deadlines set in Mirena IUD Litigation

Researchers Link Crohn’s Disease to Oral Contraceptive use

Researchers Link Crohn’s Disease to Oral Contraceptive use

Researchers Link Crohn’s Disease to Oral Contraceptive use


Taking birth control pills for five years or longer may cause Crohn’s disease, an incurable and often debilitating digestive system disease.

Crohn’s is a painful inflammation of the digestive system that is most commonly found in the intestines. Crohn’s patients have difficulty digesting food and suffer from diarrhea, fatigue and anemia. There is no cure for the illness, and it can be so painful that sufferers have been known to commit suicide to escape the agony. At least two Britons have traveled to the controversial Dignitas clinic in Switzerland to end their lives, according to Daily Mail. More Researchers Link Crohn’s Disease to Oral Contraceptive use

Lawsuit Alleges Propecia Hair Loss Drug Drove Man to Suicide After Four Tortured Years

Lawsuit Alleges Propecia Hair Drug Drove Man to Suicide

Lawsuit Alleges Propecia Hair Drug Drove Man to Suicide


Drug maker Merck & Co. is facing lawsuit allegations that involve suicidal thoughts and depression with Propecia, the company’s prescription hair loss drug. It is the first lawsuit of its kind.

The Plaintiff in the case is the wife of a man who committed suicide by stepping in front of an oncoming train after taking Propecia to treat male pattern hair loss for several years. She alleges that Propecia causes suicidality and depression in some of its users. According to the suit viewed by Law360, Merck & Co. never provided any information about the psychiatric side effects in on the drug’s label or in the literature the drug maker distributes about it. The suit was filed March 5 in California’s Southern District. More Lawsuit Alleges Propecia Hair Loss Drug Drove Man to Suicide After Four Tortured Years

Johnson & Johnson Unit Slapped with $2.5 Million Judgment Over Allegations That the Drug Risperdal Causes Breast Growth in Men

A Johnson & Johnson (J&J) unit has been slapped with a $2.5 million judgment over allegations that the company failed to warn the family of an autistic boy and his doctors about the risks of hormonal imbalances and breast growth associated with the drug Risperdal.

A Philadelphia County Court of Common Pleas jury slammed Janssen Pharmaceuticals with the decision on Tuesday after hearing evidence that J&J’s Janssen Pharmaceuticals unit had spent years trying to cover up data that showed Risperdal could cause breast growth in adolescent males, known as gynecomastia. Thousands of product liability lawsuits over the drug are pending across the country. Tuesday’s verdict is the first, according to Law360. More Johnson & Johnson Unit Slapped with $2.5 Million Judgment Over Allegations That the Drug Risperdal Causes Breast Growth in Men

Federal Judge sets Yaz Birth Control Trial Date, Accuses Bayer of Trying to “Wear Everyone Down”

Judge sets Yaz Birth Control Trial Date

Judge sets Yaz Birth Control Trial Date


An Illinois federal judge overseeing the Yaz birth control multidistrict litigation (MDL) set a trial date on Friday for one of the suits in the litigation.

The MDL involves allegations that Bayer HealthCare Pharmaceuticals, Inc.’s Yaz birth control drug causes strokes. In an order viewed by Law360, U.S. District Judge David R. Herndon said that Bayer had failed to properly conduct analyses or negotiations in certain cases alleging the drugs cause blood clots. He said that he believed that Bayer’s strategy was one of “attrition,” and that it amounted to “wearing everyone down over time.” More Federal Judge sets Yaz Birth Control Trial Date, Accuses Bayer of Trying to “Wear Everyone Down”

Mass Tort Involving 75 Xarelto Cases is Created in Philadelphia

A mass tort has been organized in Philadelphia surrounding the blood-thinning drug Xarelto, which has been alleged to cause uncontrollable and sometimes fatal bleeding.

Approximately 75 Xarelto cases were transferred to the Philadelphia Court of Common Pleas’ Complex Litigation Center by the court’s Judge Kevin Dougherty. The lawsuits are filed against Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals and Bayer HealthCare Pharmaceuticals, according to The Legal Intelligencer (The Legal). More Mass Tort Involving 75 Xarelto Cases is Created in Philadelphia

National Law Firm, Parker Waichman LLP, Seeks Increased Transparency and Ethics from the Pharmaceutical Industry in the New Year

In the new year, Parker Waichman LLP hopes for increased testing, safety, and efficacy in the processes and promotions used by Big Pharma so that consumers may be confident that they are receiving safe and effective medications that were ethically developed, tested, and marketed.

Parker Waichman, a national law firm that has long been an advocate for victims of defective medications is urging the pharmaceutical industry, as we approach a new year, to step up the ways in which it develops, tests, inspects, and markets medications.

In the new year, Parker Waichman is seeking increased transparency and accountability from all drug makers, with the hope that patient welfare is made the key priority and placed before drug approval activities and profits.
More National Law Firm, Parker Waichman LLP, Seeks Increased Transparency and Ethics from the Pharmaceutical Industry in the New Year

Women with Multiple Sclerosis who Have a Higher BMI are at Higher Risk for Lymphopenia, Studies Show

Researchers in Germany and Sweden have found that some female patients taking the multiple sclerosis (MS) drug Gilenya (fingolomid) may be at increased risk for lymphopenia, a condition that affects the immune system.

Lymphopenia (also known as lymphocytopenia) is a condition in which a patient has a deficiency of lymphocytes, which play a vital role in supporting immune system function. Gilenya has been known to reduce the level of circulating lymphocytes, and one of the most common side effects of the drug reported by the U.S. Food and Drug Administration (FDA) and the drug’s manufacturer, Novartis Pharma Stein AG, is infections. Lower lymphocyte numbers make the patient more susceptible to infection, according to EmaxHealth.com. More Women with Multiple Sclerosis who Have a Higher BMI are at Higher Risk for Lymphopenia, Studies Show